Pathways’ Picks November 17: Big Week in Washington, Aussie Reclassifications, China Picks, and More

article image

In this week’s roundup: Looking for upclassifications in six important device categories in Australia; MCIT repeal will lead to stakeholder meetings and potential congressional action; Cures 2.0, real world evidence, and decentralized trials; Califf nomination; FDA COVID-19 diagnostic updates; China targets next-gen sequencing standards, digital therapeutics, and more.

Next Picks

What we’re watching for:

Australia reclassifications. New rules underlying risk classifications for multiple device categories are set to kick in on November 25 in Australia. In general, the changes will result in higher risk classes for six targeted device categories:


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: